Literature DB >> 31611204

Baseline Interleukin-6 and Erythrocyte Sedimentation Rate Can Predict Clinical Response of TNF Inhibitor Treatment in Patients with Ankylosing Spondylitis.

Yidian Dong1, Jialong Guo1, Liqi Bi2.   

Abstract

OBJECTIVE: The objective of this study is to investigate the baseline predictors of clinical response from tumor necrosis factor (TNF) inhibitor within ankylosing spondylitis (AS) patients.
METHODS: We selected 60 AS patients and 24 healthy individuals. The interleukin (IL)-1β, IL-6, IL-17A and TNF-α levels were measured using the cytometric bead array. The receiver operating characteristic curve was used to analyze the cut off values of baseline predictors. A binary logistic regression test was used to investigate the association between baseline predictors and clinical response.
RESULTS: At baseline, the IL-1β, IL-6 and TNF-α level were positively correlated with disease activity. After 12 weeks of treatment, good responders had lower baseline IL-6 level and erythrocyte sedimentation rate (ESR) than non/poor responders. The cut off value of baseline IL-6 level and ESR to predict clinical response of TNF inhibitor treatment were 9.05 pg/mL and 47.00 mm/h, respectively. Binary logistic regression found that baseline IL-6 levels and ESR had an adverse relationship with clinical response, and the combination of IL-6 level and ESR could predict clinical response more effectively.
CONCLUSIONS: The baseline IL-6 level and ESR can predict the clinical response of TNF inhibitor treatment within AS patients, which might facilitate the selection and adjustment of medication regimens for subjects.
© 2019 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  IL-6; ankylosing spondylitis; biosimilar; erythrocyte sedimentation rate; etanercept

Mesh:

Substances:

Year:  2019        PMID: 31611204

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.

Authors:  Rajula Gaur; Kofi A Mensah; Jason Stricker; Mary Adams; Anastasia Parton; Dorota Cedzik; Jamie Connarn; Michael Thomas; Gerald Horan; Peter Schafer; Stuart Mair; Maria Palmisano; Francisco Ramírez-Valle
Journal:  Arthritis Res Ther       Date:  2022-08-18       Impact factor: 5.606

Review 2.  Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.

Authors:  Alexandra-Diana Diaconu; Alexandr Ceasovschih; Victorița Șorodoc; Cristina Pomîrleanu; Cătălina Lionte; Laurențiu Șorodoc; Codrina Ancuța
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

3.  Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients.

Authors:  Fei Peng; Fengyun Chen; Huijun Wen; Jie Bai; Yuping Tian
Journal:  Int J Rheum Dis       Date:  2022-06-12       Impact factor: 2.558

Review 4.  Efficacy and Safety of Sinomenine Preparation for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Randomized Controlled Trials.

Authors:  Shan-Shan Lin; Chun-Xiang Liu; Jun-Hua Zhang; Hui Wang; Jing-Bo Zhai; Jing-Yuan Mao; Xian-Liang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-14       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.